A reaction is unexpected when its nature or severity is not consistent with the product's reference safety information (RSI). Which document is the RSI depends on the product:
- For a product not yet approved, the Investigator's Brochure (ICH E2A; for US trials, 21 CFR 312.32 says the investigator brochure, or the risk information in the application when there is no brochure).
- For a marketed product in the US, the current labeling (21 CFR 314.80: unexpected is "not listed in the current labeling").
Three rules follow from E2A:
- Expectedness is judged on what has been observed and documented, "not on the basis of what might be anticipated from the pharmacological properties" of the product. A reaction that makes sense for the drug's mechanism but is not in the RSI is unexpected.
- A reaction listed as rare is still listed: frequency does not make it unexpected.
- Serious and unexpected are separate questions. A serious reaction can be expected.
The products in this course are fictional; open Reference, then Products, to read their RSI.
Which document decides.